Unintended pregnancy after gonadal failure chemoprevention with gonadotropin-releasing hormone agonist in women with hematologic malignancies.
Many patients who receive co-treatment with GnRH agonists (GnRH-a) during chemotherapy treatment preserve their ovarian function and are at risk of unintended pregnancies. Therefore, it is important to offer them effective contraception. Also, pregnancies occurring after cancer therapy in women who received GnRH-a are not associated with adverse neonatal outcomes.
Castelo-Branco
Camil
C
Institut Clínic de Ginecologia, Obstetrícia i Neonatologia, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain. Electronic address: castelobranco@ub.edu.
Rabanal
Aintzane
A
Institut Clínic de Ginecologia, Obstetrícia i Neonatologia, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
Nomdedeu
Benet
B
Institut Clínic de Malalties Hematològiques i Oncològiques, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
Durán
Magda
M
Institut Clínic de Ginecologia, Obstetrícia i Neonatologia, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
Arigita
Marta
M
Institut Clínic de Ginecologia, Obstetrícia i Neonatologia, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
Balasch
Juan
J
Institut Clínic de Ginecologia, Obstetrícia i Neonatologia, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain.
D000293:Adolescent; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D016022:Case-Control Studies; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D019337:Hematologic Neoplasms / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007231:Infant, Newborn; D008875:Middle Aged; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000453:epidemiology; D011256:Pregnancy Outcome; D049168:Pregnancy, Unplanned; D016649:Primary Ovarian Insufficiency / Q000517:prevention & control*; D013997:Time Factors; D017329:Triptorelin Pamoate / Q000627:therapeutic use*; D014747:Vinblastine / Q000627:therapeutic use; D055815:Young Adult
D018931:Antineoplastic Agents, Hormonal; D017329:Triptorelin Pamoate; D001761:Bleomycin; D007987:Gonadotropin-Releasing Hormone; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin